van Luijt P A, Heijnsdijk E A M, Fracheboud J, Overbeek L I H, Broeders M J M, Wesseling J, den Heeten G J, de Koning H J
Department of Public Health, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
National Evaluation Team for Breast cancer screening in the Netherlands (NETB), Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Nijmegen, The Netherlands.
Breast Cancer Res. 2016 May 10;18(1):47. doi: 10.1186/s13058-016-0705-5.
The incidence of ductal carcinoma in situ (DCIS) has rapidly increased over time. The malignant potential of DCIS is dependent on its differentiation grade.
Our aim is to determine the distribution of different grades of DCIS among women screened in the mass screening programme, and women not screened in the mass screening programme, and to estimate the amount of overdiagnosis by grade of DCIS. We retrospectively included a population-based sample of 4232 women with a diagnosis of DCIS in the years 2007-2009 from the Nationwide network and registry of histopathology and cytopathology in the Netherlands. Excluded were women with concurrent invasive breast cancer, lobular carcinoma in situ and no DCIS, women recently treated for invasive breast cancer, no grade mentioned in the record, inconclusive record on invasion, and prevalent DCIS. The screening status was obtained via the screening organisations. The distribution of grades was incorporated in the well-established and validated microsimulation model MISCAN.
Overall, 17.7 % of DCIS were low grade, 31.4 % intermediate grade, and 50.9 % high grade. This distribution did not differ by screening status, but did vary by age. Older women were more likely to have low-grade DCIS than younger women. Overdiagnosis as a proportion of all cancers in women of the screening age was 61 % for low-grade, 57 % for intermediate-grade, 45 % for high-grade DCIS. For women age 50-60 years with a high-grade DCIS this overdiagnosis rate was 21-29 %, compared to 50-66 % in women age 60-75 years with high-grade DCIS.
Amongst the rapidly increasing numbers of DCIS diagnosed each year is a significant number of overdiagnosed cases. Tailoring treatment to the probability of progression is the next step to preventing overtreatment. The basis of this tailoring could be DCIS grade and age.
导管原位癌(DCIS)的发病率随时间迅速上升。DCIS的恶性潜能取决于其分化程度。
我们的目的是确定在大规模筛查项目中接受筛查的女性和未接受大规模筛查项目的女性中不同分级DCIS的分布情况,并按DCIS分级估计过度诊断的数量。我们回顾性纳入了2007年至2009年期间来自荷兰全国组织病理学和细胞病理学网络及登记处的4232例诊断为DCIS的女性人群样本。排除了合并浸润性乳腺癌、小叶原位癌且无DCIS的女性、近期接受过浸润性乳腺癌治疗的女性、记录中未提及分级的女性、关于浸润情况记录不明确的女性以及既往存在的DCIS。通过筛查机构获取筛查状态。将分级分布纳入成熟且经过验证的微观模拟模型MISCAN。
总体而言,17.7%的DCIS为低级别,31.4%为中级,50.9%为高级。这种分布在筛查状态方面无差异,但在年龄方面有所不同。老年女性比年轻女性更有可能患低级别DCIS。在筛查年龄的女性中,低级别DCIS的过度诊断占所有癌症的比例为61%,中级为57%,高级为45%。对于50至60岁患有高级别DCIS的女性,该过度诊断率为21%至29%,而60至75岁患有高级别DCIS的女性为50%至66%。
在每年诊断出的DCIS数量迅速增加的情况下,存在大量过度诊断的病例。根据进展可能性调整治疗是预防过度治疗的下一步。这种调整的依据可以是DCIS分级和年龄。